Syndax Pharma: Two Drug Launches Fuel Transformational Growth

Group 1 - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck from 2009 to 2013 and has experience in biotech startups including Theravance and Aspira [1] - Brendan is a co-founder of 1200 Pharma, which spun out of Caltech and received significant investment in the eight figures [1] Group 2 - The author has a beneficial long position in the shares of SNDX and INCY [2] - The article expresses the author's own opinions and is not receiving compensation from any mentioned companies [2]